文献速递炎症性肠病消化道肿瘤与早癌消化内镜

粪便样本特定位点DNA甲基化分析可检测炎症性肠病患者的结直肠癌和高级别异型增生

Analysis of DNA Methylation at Specific Loci in Stool Samples Detects Colorectal Cancer and High-Grade Dysplasia in Patients With Inflammatory Bowel Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-05-15

该研究利用美国病例对照研究和2个欧洲监测队列的粪便样本,分析BMP3、NDRG4、VAV3和SFMBT2相对于ZDHHC1的甲基化水平,发现BMP3和VAV3甲基化水平可识别结直肠癌和高级别异型增生,曲线下面积0.91(95%CI 0.77-1.00),灵敏度92%(95%CI 60%-100%),特异度90%(95%CI 86%-93%),假阳性率在不同队列间无显著差异(P=0.60)。

要点

  • 粪便BMP3和VAV3相对于ZDHHC1的甲基化水平可检测IBD患者的结直肠癌和高级别异型增生。
  • 曲线下面积0.91(95%CI 0.77-1.00),灵敏度92%(95%CI 60%-100%),特异度90%(95%CI 86%-93%)。
  • 应用全样本90%特异度截断值时,病例对照、转诊队列和人群队列的假阳性率无显著差异(P=0.60)。

核心结论

  • 在3项独立研究共332例IBD患者的粪便样本分析中,BMP3和VAV3相对于ZDHHC1的甲基化水平与结直肠癌和高级别异型增生的检测相关。
  • 这些甲基化模式识别结直肠癌和高级别异型增生的特异度超过90%,可能用于结直肠癌监测。

研究设计与样本

  • 研究获取美国病例对照研究和2个欧洲监测队列(转诊或人群基础)的缓冲冷冻粪便样本,纳入慢性溃疡性结肠炎(n=248)、克罗恩病(n=82)、不确定性结肠炎(n=2)或IBD合并原发性硬化性胆管炎(n=38)患者。
  • 粪便样本在结肠镜检查肠道准备前或结肠镜检查后至少1周采集。
  • 无肿瘤的IBD患者粪便作为对照(n=291)。
  • 粪便DNA经亚硫酸氢盐处理后,采用多重定量等位基因特异性实时靶标和信号扩增法检测。
  • 分析BMP3、NDRG4、VAV3和SFMBT2相对于ZDHHC1的甲基化水平,并在结直肠癌或高级别异型增生患者与对照之间比较。

主要发现

  • BMP3和VAV3相对于ZDHHC1的甲基化水平识别结直肠癌和高级别异型增生的曲线下面积为0.91(95%CI 0.77-1.00)。
  • 这些基因特定启动子区域的甲基化水平识别了12例结直肠癌和高级别异型增生患者中的11例,灵敏度92%(95%CI 60%-100%),特异度90%(95%CI 86%-93%)。
  • 应用全样本90%特异度截断值时,病例对照研究、转诊队列和人群队列研究的假阳性率无显著差异(P=0.60)。

关键数值与推荐

  • BMP3和VAV3相对于ZDHHC1的甲基化水平识别结直肠癌和高级别异型增生的曲线下面积为0.91(95%CI 0.77-1.00)。
  • 灵敏度92%(95%CI 60%-100%),特异度90%(95%CI 86%-93%)。
  • 全样本90%特异度截断值下,不同研究间假阳性率无显著差异(P=0.60)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn's disease, are at increased risk for colorectal cancer (CRC). Analyses of DNA methylation patterns in stool samples have been reported to detect CRC in patients with IBD. We sought to validate these findings in larger cohorts and assess the accuracy of analysis of DNA methylation patterns in stool for detection of CRC and high-grade dysplasia (HGD) normalized to methylation level at ZDHHC1. METHODS: We obtained buffered, frozen stool samples from a US case-control study and from 2 European surveillance cohorts (referral or population based) of patients with chronic ulcerative colitis (n = 248), Crohn's disease (n = 82), indeterminate colitis (n = 2), or IBD with primary sclerosing cholangitis (n = 38). Stool samples were collected before bowel preparation for colonoscopy or at least 1 week after colonoscopy. Among the study samples, stools from individuals with IBD but without neoplasia were used as controls (n = 291). DNA was isolated from stool, exposed to bisulfite, and then assayed by multiplex quantitative allele-specific real-time target and signal amplification. We analyzed methylation levels of BMP3, NDRG4, VAV3, and SFMBT2 relative to the methylation level of ZDHHC1, and compared these between patients with CRC or HGD and controls. RESULTS: Levels of methylation at BMP3 and VAV3, relative to ZDHHC1 methylation, identified patients with CRC and HGD with an area under the curve value of 0.91 (95% CI, 0.77-1.00). Methylation levels at specific promotor regions of these genes identified 11 of the 12 patients with CRC and HGD, with 92% sensitivity (95% CI, 60%-100%) and 90% specificity (95% CI, 86%-93%). The proportion of false-positive results did not differ significantly among the case-control, referral cohort, and population cohort studies (P = .60) when the 90% specificity cut-off from the whole sample set was applied. CONCLUSIONS: In an analysis of stool samples from 3 independent studies of 332 patients with IBD, we associated levels of methylation at 2 genes (BMP3 and VAV3), relative to level of methylation at ZDHHC1, with detection of CRC and HGD. These methylation patterns identified patients with CRC and HGD with more than 90% specificity, and might be used in CRC surveillance.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kisiel JB, Klepp P, Allawi HT, et al. Analysis of DNA Methylation at Specific Loci in Stool Samples Detects Colorectal Cancer and High-Grade Dysplasia in Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2018. PMID: 29775793. doi:10.1016/j.cgh.2018.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。